Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Financing Activities (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Cash from Financing Activities for 12 consecutive years, with $353000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities changed N/A year-over-year to $353000.0, compared with a TTM value of $298000.0 through Sep 2025, up 446.51%, and an annual FY2024 reading of -$206000.0, down 153.51% over the prior year.
  • Cash from Financing Activities was $353000.0 for Q3 2025 at Lisata Therapeutics, up from $64000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $452000.0 in Q2 2023 and bottomed at -$142000.0 in Q1 2024.
  • Average Cash from Financing Activities over 3 years is $57300.0, with a median of $9000.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities tumbled 500.0% in 2024, then soared 100.0% in 2025.
  • Year by year, Cash from Financing Activities stood at $24000.0 in 2023, then crashed by 500.0% to -$96000.0 in 2024, then soared by 467.71% to $353000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for LSTA at $353000.0 in Q3 2025, $64000.0 in Q2 2025, and -$23000.0 in Q1 2025.